Tissue-based next generation sequencing: application in a universal healthcare system.

Abstract excerpt

In the context of solid tumours, the evolution of cancer therapies to more targeted and nuanced approaches has led to the impetus for personalised medicine. The targets for these therapies are largely based on the driving genetic mutations of the tumours. To track these multiple driving mutations the use of next generation sequencing (NGS) coupled with a morphomolecular approach to tumours, has the potential to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Insurance, Health
• Share to Mutation
• Share to Clinical Trials as Topic